A Pooled Analysis of Fall Incidence From Placebo‐Controlled Trials of Denosumab

Recent studies suggest that the RANK/RANKL system impacts muscle function and/or mass. In the pivotal placebo‐controlled fracture trial of the RANKL inhibitor denosumab in women with postmenopausal osteoporosis, treatment was associated with a lower incidence of non‐fracture‐related falls (p = 0.02)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chotiyarnwong, Pojchong, McCloskey, Eugene, Eastell, Richard, McClung, Michael R, Gielen, Evelien, Gostage, John, McDermott, Michele, Chines, Arkadi, Huang, Shuang, Cummings, Steven R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328365/
https://www.ncbi.nlm.nih.gov/pubmed/31999376
http://dx.doi.org/10.1002/jbmr.3972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328365/
https://www.ncbi.nlm.nih.gov/pubmed/31999376
http://dx.doi.org/10.1002/jbmr.3972

Ejemplares similares